NYSE: GWW Q4 2025 Earnings Call February 3, 2026 © 2026 W.W. Grainger, Inc. Safe Harbor Statement and Non-GAAP Financial Measures All statements in this communication, other than those relating to historical facts, are "forward-looking statements" under the federal securities laws. Forward-looking statements can generally be identified by their use of terms such as "anticipate," "estimate," "believe," "expect," "could," "forecast," "may," "intend," "plan," "predict," "project," "will," or "would," and simil ...

The collaboration leverages Keysight's high-speed digital test solutions, including the M8050A High- Performance Bit Error Ratio Tester (BERT) and DCA-X Sampling Oscilloscopes, which are crucial for generating and analyzing complex 120 GBaud PAM4 signals required for 1.6 Terabit speeds. Sean Park, CEO, Point2Technology, said: "A strategic partnership with Keysight gives us access to world- class engineering tools and support, allowing us to accelerate our e-Tube product development cycles. The confidence th ...

Celestica (NYSE:CLS) Q4 2025 Earnings call January 29, 2026 08:00 AM ET Speaker4Ladies and gentlemen, thank you for joining us, and welcome to the Celestica Q4 2025 financial results and conference call. After today's prepared remarks, we will host a question and answer session. If you'd like to ask a question, please raise your hand. If you have dialed in to today's call, please press star nine to raise your hand and star six to unmute when called upon. I will now hand the conference over to Matthew Palata ...

TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that Lawrence Guy is joining the Company’s Board of Directors (“the Board”). Mr. Guy’s appointment further strengthens the Board with his deep experience in capital markets, investment management, and public-c ...

Summary of Fortrea Holdings Conference Call Company Overview - **Company Name**: Fortrea Holdings - **Industry**: Contract Research Organization (CRO) - **Background**: Fortrea was spun out from Labcorp in 2023, with roots tracing back to Covance, which Labcorp acquired in 2015. The company focuses on advancing clinical development and providing innovative solutions for drug development [2][3]. Core Points and Arguments - **Value Proposition**: Fortrea positions itself as a pure-play global CRO with decades of experience, capable of serving a diverse client base, from large pharmaceutical companies to small biotech firms [4][5]. - **Market Environment**: The overall market for pharmaceutical R&D investments is cautiously optimistic, with expected growth rates of approximately 3%-4% in the near term, driven by big pharma's renewed focus on R&D and improvements in biotech funding [6][24][26]. - **Service Offerings**: Fortrea provides a comprehensive suite of services across the clinical trial continuum, including clinical operations, data management, biostatistics, and consulting services, with expertise in over 20 therapeutic areas [8][12]. - **Technological Integration**: The company is modernizing study delivery by leveraging AI and machine learning to enhance productivity and quality in clinical trials [5][14]. - **Client Relationships**: Fortrea emphasizes building strong, long-term relationships with clients, which is reflected in its balanced client base of approximately 50% large pharma and 50% biotech [13][39]. Important but Overlooked Content - **Operational Focus**: The management team is concentrating on three pillars of excellence: commercial, operational, and financial, to drive sustained revenue growth and margin expansion [15][17]. - **Cost Management**: Fortrea aims to achieve approximately $150 million in gross cost savings, with a focus on right-sizing the organization while also driving revenue growth [32][33]. - **Market Trends**: There is a shift towards hybrid outsourcing models, particularly among mid-sized biotech companies, which Fortrea is well-positioned to accommodate [28]. - **Pricing Discipline**: The CRO market is competitive, and while pricing plays a significant role in FSP (Functional Service Provider) contracts, Fortrea maintains a focus on quality and team performance over price alone [34][35]. - **Capital Allocation**: Post-spin, Fortrea is focused on improving its debt position and making targeted organic investments to enhance productivity and relevance in the market [36][38]. Conclusion - **Key Message**: Fortrea has successfully transitioned out of its spin-off phase, is focused on execution and customer satisfaction, and is optimistic about returning to sustainable growth as market conditions improve [39].

As filed with the U.S. Securities and Exchange Commission on December 19, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ––––––––––––––––––––––––––––––––––––––– FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ––––––––––––––––––––––––––––––––––––––– Brookline Capital Acquisition Corp II (Exact name of registrant as specified in its charter) ––––––––––––––––––––––––––––––––––––––– | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State ...

While the artificial intelligence (AI) chipmaker has had an incredible run, another household name could leapfrog into first place.There's no denying the impact artificial intelligence (AI) has had on the technology landscape over the past several years. Many of the world's most valuable companies by market cap have unmistakable ties to AI and have profited handsomely from the advent of this technology.Chief among those has been Nvidia (NVDA 1.55%). The company's graphics processing units (GPUs) were origin ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $701.3 million, a 3.9% increase compared to the prior year quarter, driven by growth in both clinical pharmacology and clinical development businesses [19][30] - Adjusted EBITDA for the quarter was $50.7 million, down from $64.2 million in the prior year period, primarily due to lower margins related to project mix and increased pass-through costs [23][30] - The company reported a net loss of $15.9 million for Q3 2025, an improvement from a net loss of $18.5 million in the prior year [23] - The book-to-bill ratio improved to 1.13 times, with a backlog exceeding $7.6 billion [5][22] Business Line Data and Key Metrics Changes - The clinical pharmacology business saw increased demand and higher levels of pass-through costs, contributing to revenue growth [19] - The clinical development segment also experienced growth due to new business awards, although it was partially offset by lower fee-for-service (FFP) revenue [19] - Average contract size in clinical pharmacology continues to increase, reflecting expertise in managing complex early-phase clinical trials [9] Market Data and Key Metrics Changes - Demand for services has shown signs of improvement, with growth in clinical trial starts and increased biotech funding in Q3 2025 [6] - Win rates with biotech clients doubled compared to the prior quarter, indicating a positive trend in client engagement [6][37] Company Strategy and Development Direction - The company is focusing on three critical pillars: commercial excellence, operational excellence, and financial excellence, to drive growth and improve margins [15][16] - A renewed focus on client-facing activities and employee engagement has been emphasized, with efforts to deepen relationships with clients and enhance operational efficiency [12][15] - The company is committed to maintaining a healthy balance sheet and financial flexibility, including debt repayment initiatives [7][28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the improving demand environment and the resilience of biopharma clients, despite competitive pressures [6][40] - The company anticipates continued growth in its backlog and is focused on optimizing its capital structure and cash flow [26][30] - There is a commitment to right-sizing the organization and enhancing operational efficiency to achieve industry-standard margins [54][56] Other Important Information - The company has captured over $95 million in gross savings year-to-date, contributing to improvements in EBITDA [29] - The introduction of new technology and AI initiatives is expected to enhance productivity and operational excellence [11][12] Q&A Session Summary Question: Update on pre-spend vs post-spend awards - Management noted that there has been progress in right-sizing contracts and focusing on out-of-scope work, with improved results from these efforts [32][33] Question: Details on new-to-Fortrea clients - RFP volume from new clients increased by almost 40% quarter-over-quarter, with win rates for biotech clients doubling [37][38] Question: Bookings backdrop between large pharma and small biotech - Management observed neutral to favorable trends in both segments, with improved decision-making timelines in biotech [39][40] Question: Changes in competitive intensity and pricing environment - The pricing environment remains competitive but disciplined, with a focus on leading with science and operational expertise rather than aggressive pricing [41] Question: Margin leverage and pricing strategy - Management aims to hold prices where possible, with a focus on growing direct service fee revenue to improve margins [45][46] Question: Anecdotes on industry environment - Positive anecdotes were shared regarding decision-making timelines in both biotech and large pharma, indicating a return to more stable operational processes [62]

Core Insights - AmpliTech Group is actively engaging in the ORAN 5G ecosystem by joining the ORAN Alliance and Telecom Infra Project, enhancing its position in the market [1][4] - The company is converting significant Letters of Intent (LOIs) into actual business, indicating strong customer demand for its ORAN 5G solutions [2][4] - The ORAN market is experiencing rapid growth, projected to reach $45.70 billion by 2032, with AmpliTech positioned to capitalize on this trend [3] Company Developments - AmpliTech Group's 5G division has secured a $78 million LOI, resulting in over $2 million in funded orders, and a $40 million LOI that has generated more than half of its projected value in funded orders [2] - The company is integrating AI and ML capabilities into its ORAN 5G and Wi-Fi 6/7 solutions, which enhances network optimization, energy efficiency, and security [2] - AmpliTech is showcasing its advanced 64T64R MIMO radio technology, designed for high-density areas and military applications, at the upcoming Network X Conference in Paris [2][4] Industry Trends - The ORAN market was valued at approximately $2.92 billion in 2024 and is expected to grow at a CAGR of 41.03%, indicating a significant opportunity for suppliers [3] - By 2028, ORAN is anticipated to account for nearly one-third of all global RAN deployments, reflecting the increasing adoption of advanced wireless technology [3] - The U.S. 5G New Radio RAN market was valued at $0.9 billion in 2024, showcasing steady growth driven by the adoption of advanced wireless technology [3]

Core Insights - The rising demand for business process outsourcing (BPO) is driven by flexibility and low costs, with trends like IoT, cloud computing, AI, and ML transforming the sector [1][4][6] Industry Overview - Outsourcing involves delegating internal operations to external resources to enhance operational efficiency, primarily catering to small and medium-sized enterprises [3] - Services include HR support, payroll management, benefits administration, retirement planning, and insurance services, allowing businesses to focus on core competencies [3] Future Trends - There is consistent growth in business process and IT outsourcing due to increased demand for flexibility, lower costs, and improved service quality [4] - The shortage of in-house engineering talent is expected to drive the outsourcing trend [4] - The urgency for robust cybersecurity measures is increasing, leading companies to outsource cybersecurity services to mitigate risks and maintain compliance [5] Industry Performance - The Zacks Outsourcing industry currently holds a Zacks Industry Rank of 35, placing it in the top 14% of 246 Zacks industries, indicating bright near-term prospects [7] - Over the past year, the Zacks Outsourcing industry has underperformed compared to the broader Zacks Business Services sector and the S&P 500, declining by 1.9% against the sector's 3.7% growth and the S&P 500's 17.7% growth [9][10] Valuation Metrics - The industry is trading at a forward 12-month price-to-earnings (P/E) ratio of 16.43X, lower than the S&P 500's 23.34X and the sector's 21.4X [13] Promising Companies - **Brink's Company (BCO)**: Provides cash and valuables management services with a 5% organic growth rate in Q2 2025, driven by strong demand for precious metals and successful customer acquisition [17][19] - **Barrett Business Services, Inc. (BBSI)**: A Professional Employer Organization with a record increase of 10,100 worksite employees added year-over-year in Q2 2025, supported by strong client retention and new product adoption [20][21] - **Capgemini SE (CGEMY)**: Focuses on business transformation and consulting, with a robust book-to-bill ratio of 1.08 and a contribution of nearly 7% from GenAI and Agentic AI in Q2 2025 [22][23][25]